---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-26-000005"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:54:34.763842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20

## Summary
- Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).
- Full-year 2025: net sales $3.074B (+6.3%); diluted EPS $6.79 (+1.5%), adj-diluted EPS $7.29 (+8.0%).
- FY2026 guidance: net sales $3.215B-$3.275B (4.6%-6.5% growth); adj-diluted EPS $7.85-$8.20 (+7.7%-12.5%).
- Operating cash flow $754.8M (+15.5%); free cash flow $468.9M (+69.6%); repurchased 552,593 shares for $134M.
- Expects mid-2026 close of SmartDose 3.5mL sale to AbbVie; device generated $55M in H2 2025.

## SEC filing metadata
- accession: 0000105770-26-000005
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/0000105770-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/wst-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-26-000005
- JSON: https://secwatch.observer/filing/0000105770-26-000005.json
- Plain text: https://secwatch.observer/filing/0000105770-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.